Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects

Prediction of Creatinine Clearance from Serum Creatinine

Donald W. Cockcroft, Henry Gault · ˜The œNephron journals/Nephron journals · 2008 · 15.4K citations

Pharmacy, Nephrology, Pharmacokinetics +15

Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology

Valentı́n Fuster, Lars Rydén, Richard Asinger et al. · European Heart Journal · 2001 · 493 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects

David Gustafsson, Jan-Erik Nyström, Stefan Carlsson et al. · Thrombosis Research · 2001 · 302 citations

Medicine, Pharmacokinetics, Pharmacology +17

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

Bengt I. Eriksson, Peter Kälebo, David Bergqvisty et al. · The Lancet · 2002 · 248 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty

Charles W. Francis, Bruce L. Davidson, Scott D. Berkowitz et al. · Annals of Internal Medicine · 2002 · 210 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15